S-1/A: Dror Ortho-Design Seeks Nasdaq Listing, $13M Public Offering

Dror Ortho-Design, a pre-revenue medical device company, is pursuing a public offering of up to 3.6 million shares and prefunded warrants to raise $13 million, alongside a 1-for-550 reverse stock split, while facing significant financial challenges and a going concern doubt.

Summary

• Dror Ortho-Design is offering up to 3,636,364 shares of common stock and prefunded warrants to purchase an equal number of shares, at an assumed public offering price of $4.13 per share.
• The company expects to receive net proceeds of approximately $13.0 million from this offering, or $15.0 million if the underwriters' over-allotment option is fully exercised.
• A 1-for-550 reverse stock split is expected to be effected prior to or upon the effectiveness of the registration statement.
• The company has applied to list its common stock on the Nasdaq Capital Market under the symbol DROR, and will not proceed with the offering if the listing is not approved.
• Dror Ortho-Design has developed ZSmile, a proprietary AI-based platform for smile correction intended for nighttime use, which received 510(k) clearance from the FDA in February 2026.
• The company is in the development stage, does not currently generate revenues, and anticipates continued significant losses.
• As of December 31, 2025, the company had cash of $228,540, a working capital deficit of $2.7 million, and an accumulated deficit of $22.05 million.
• Net losses were $2.5 million for the year ended December 31, 2025, and $5.8 million for the year ended December 31, 2024.
• The company used $2.1 million in cash from operations during the twelve months ended December 31, 2025.
• Bridge loans totaling $1.75 million were received from existing investors during 2025, with an additional $200,000 received in February 2026, all bearing 0% interest and extended to June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the company's pre-revenue status, significant recurring losses, critical liquidity issues, and the auditor's going concern doubt, despite the promising FDA clearance for its product and large market opportunity.

Positives

• The ZSmile platform, an AI-based solution for smile correction, received 510(k) clearance from the FDA in February 2026, allowing commercialization in the U.S.
• The global clear aligners market is estimated at $8.3 billion in 2025 and projected to reach $56.8 billion by 2033, growing at a CAGR of 26.95%.
• ZSmile targets the 'social six' malocclusions, representing a potential addressable market of $17 billion (30% of the projected 2033 market).
• The platform expands the target distribution channel to include general dentists, who outnumber orthodontists approximately 15 to 1 in the U.S., significantly increasing the practitioner market.
• ZSmile uses a single smart aligner with pulsating air for nighttime use, offering a discreet, less intrusive, and less painful alternative to existing 12-15 month, all-day aligner solutions.
• The company holds several patents for its technology, including the use of pulsating air and 3D printing for aligner production.
• The ZSmile AI Cloud is designed to convert 2D smartphone videos into 3D models for initial analysis and remote monitoring, potentially replacing intraoral scans for certain cases.
• The company has a research and development team with expertise in AI, medical device development, data science, and imaging systems, including professionals from elite Israeli intelligence units.
• The hardware and systems development team is part of Aran Research Development Prototypes Ltd., an ISO 13485 certified firm with an ISO 7 cleanroom and FDA-compliant manufacturing facilities.

Negatives

• The company is in the development stage, does not generate revenues, and has incurred recurring net operating losses since inception, totaling an accumulated deficit of $22.05 million as of December 31, 2025.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient liquidity.
• As of December 31, 2025, the company had only $228,540 in cash and a working capital deficit of $2.7 million, indicating a critical need for additional capital.
• The company's future operations are dependent on successfully raising additional capital, which is not assured, and may require delaying or eliminating R&D programs if unsuccessful.
• New investors in the public offering will experience immediate dilution of $2.25 per share based on the assumed public offering price of $4.13 per share.
• The company's common stock is currently quoted on the OTC Pink Limited Market, which has limited liquidity, and there is no assurance the Nasdaq listing application will be approved.
• The company's business model is unproven, and there is no guarantee that its products and technologies will achieve wide market acceptance by consumers or dental professionals.
• The company faces intense competition from large, internationally established aligner companies with greater resources and existing distribution channels.
• The management team has a relative lack of U.S. public company experience, which may pose challenges in complying with U.S. securities laws and GAAP.

Risks

• The company's financial statements have been prepared on a going concern basis, and it must raise additional capital to fund operations to continue as a going concern.
• Operations are conducted in Israel, making the business directly affected by economic, political, geopolitical, and military conditions in the region, including ongoing conflicts and potential supply chain disruptions.
• Global and regional economic conditions, including inflation, currency fluctuations, and recessions, could materially affect business, results of operations, and financial condition.
• The company is in the development stage, is not generating revenues, and has no operating history in manufacturing and distribution of orthodontic medical devices for consumer use.
• Products and technologies may not be accepted by intended commercial consumers, which could harm future financial performance.
• Continued operating losses are expected, and future profitability is uncertain.
• Net revenues will depend primarily on the ZSmile Platform, and any decline in sales or average selling price may adversely affect net revenues, gross margin, and net income.
• The company will face competition from large internationally established aligner companies whose products have been widely accepted.
• Growth and future success depend on the ability to enhance the Platform or to develop, obtain regulatory clearance for, successfully introduce, and achieve market acceptance of new products and services.
• Operating risks include excess or constrained capacity and operational inefficiencies, which could adversely affect results of operations.
• Issues with product development, IT system integration, or cyberattacks could disrupt operations and materially impact business and operating results.
• Complying with regulations enforced by the U.S. Food and Drug Administration (FDA) and other regulatory authorities is expensive and time-consuming, and failure to comply could result in substantial penalties.
• The company may not receive necessary authorizations to market any future new products, and any failure to timely do so may adversely affect its ability to grow.
• Certain modifications to products may require new 510(k) clearance or other marketing authorizations.
• Ongoing changes in healthcare regulation could negatively affect revenues, business, and financial condition.
• The company is subject to federal, state, and foreign fraud and abuse laws, health information privacy and security laws, and transparency laws, which, if violated, could subject it to substantial penalties.
• Success depends in part on proprietary technology, and inability to successfully enforce intellectual property rights could harm the competitive position.
• The relative lack of U.S. public company experience of the management team may put the company at a competitive disadvantage.
• The common stock is not currently listed on any major stock exchange, and there is a limited market for shares, which could be subject to wide fluctuations.
• The company is subject to penny stock rules, making shares more difficult to sell.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell the stock.
• The company may need additional financing which may not be available on acceptable terms, potentially diluting existing investments.
• The board of directors can authorize the issuance of preferred stock, which could diminish the rights of common stockholders and make a change of control more difficult.
• Anti-takeover provisions under Delaware corporate law may make it difficult for stockholders to replace or remove the board and could deter or delay third parties from acquiring the company.
• Future sales of significant amounts of common stock may depress the stock price.
• Changes in, or interpretations of, accounting rules and regulations could result in unfavorable accounting charges.
• A material weakness in internal control over financial reporting has been identified due to limited personnel and lack of segregation of duties, and the absence of a Chief Financial Officer.
• The effective tax rate may vary significantly from period to period due to global economic environment, changes in legal entity structure, tax laws, and other factors.

Future Outlook

The company expects to continue incurring significant operating losses in the foreseeable future as it increases expenditures for the development and marketing of the ZSmile Platform. It intends to spend approximately $1 million over the next 12 months on software and hardware development, regulatory approvals, and IP protection. The company aims to achieve profitability on a sustained basis, but the timeline is uncertain. Future success depends on market acceptance of its teledentistry model and ability to compete with established aligner companies. The company plans to use the net proceeds from the offering primarily for working capital and general corporate purposes.

Management Comments

• We have reimagined the way people can correct their smile and plan to disrupt the aligner market by offering millions of people a revolutionary alternative.
• We believe that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions.
• We believe that recent rapid advancements in technology have made traditional aligner solutions no longer the most effective treatment option for smile correction.
• The name ZSmile is intended to communicate that people can correct their smile while they sleep or colloquially getting some zzzs.
• We intend to spend approximately $1 million over the next 12 months on software and hardware development as well as the accompanying regulatory approvals and IP protection associated with such software and hardware projects.
• We believe that the Platform's image analysis of smartphone videos will eventually approach the level of accuracy observed in intraoral scans, potentially allowing smartphones to replace intraoral scans for certain cases.
• Our solution requires only one smart aligner to be produced for each patient, enabling us to take advantage of cost-effective 3D printing production methods with economies of scale.
• We believe that our Platform will compare favorably with respect to price, access, convenience, aesthetic appeal, comfort, duration and effectiveness of treatment, ease of use, and orthodontist chair time compared to competitors.

Industry Context

StockSavvy.ai notes that Dror Ortho-Design is entering a rapidly growing global clear aligners market, projected to expand from $8.3 billion in 2025 to $56.8 billion by 2033. The company's focus on 'social six' malocclusions and targeting general dentists, who significantly outnumber orthodontists, positions it to address a large, underserved segment. This strategy aligns with a broader industry trend towards teledentistry and increased accessibility of orthodontic care. However, the market is dominated by large, established players like Align Technologies (Invisalign), Dentsply Sirona (Byte), 3M Clarity Aligners, and Straumann Group, posing significant competitive challenges for a pre-revenue entrant.

Comparison to Industry Standards

• ZSmile's effectiveness in clinical trials was demonstrated to be consistent with results achieved by Align Technology's Invisalign clear aligners solution.
• Unlike traditional clear aligner solutions that require patients to wear 20-30 plastic aligners all day for 12-15 months, ZSmile uses only one smart aligner for nighttime use, aiming for a less painful and intrusive experience.
• The company's plan to use 3D printing for actual aligner production is a significant development, as other companies primarily use thermoforming or 3D print models, not the aligners themselves. This could offer superior precision and customizability.
• ZSmile's teledentistry model, allowing remote monitoring and treatment plan modification via a smartphone app, contrasts with traditional therapies requiring multiple in-person orthodontist visits.

Corporate Governance

Legal Proceedings

• Eliyahu (Lee) Haddad, CEO and Director, was permanently barred from association with any broker, dealer, municipal securities dealer, investment advisor, or investment company by the SEC in 1992, in connection with alleged violations of SEC rules. He is not barred from being an officer or director of a public company.
• The company is subject to routine litigation incidental to its business, but management believes no current matters would have a material adverse effect on results of operations and financial condition.

Related Party Transactions

• On July 5, 2023, the company entered into a Share Exchange Agreement with Private Dror and its shareholders, including Moshe Shvets (CTO and director) and AIGH Investment Partners (a >5% stockholder), resulting in Private Dror becoming a wholly-owned subsidiary.
• In connection with the Share Exchange and Private Placement, Eliyahu Haddad (CEO), Moshe Shvets (CTO), and AIGH received Series A Preferred Stock, Common Stock, and Private Placement Warrants.
• Bridge loans totaling $1.75 million in 2025 and an additional $200,000 in February 2026 were received from existing investors, some of whom are related parties.
• Yehuda Englander, a director, receives a monthly cash fee of $2,500 for financial and strategic consulting services and was granted options to purchase 9,597,675 shares of Common Stock.
• Chaim Ravad, a director, received $55,000 in cash fees for board member services in 2024, with the agreement terminating upon reaching this aggregate amount.
• Oriole Avenue Inc., an entity owned by Yaacov Bodner (a stockholder), received $145,000 in cash payments and warrants to purchase 10,454,500 shares of Common Stock for shareholder, investor relations, and general consultancy services.

Stakeholder Impact

• Shareholders face significant dilution from the public offering and potential future capital raises, as well as high investment risk due to the company's pre-revenue status and going concern doubt.
• Employees may face uncertainty regarding job security and future compensation given the company's financial challenges and need for additional funding.
• Future customers could benefit from the innovative ZSmile product, offering a less intrusive and painful orthodontic treatment option.
• Creditors, particularly holders of the convertible debentures, have extended maturity dates, indicating potential delays in repayment, though the public offering aims to improve liquidity.

Next Steps

• Effect a 1-for-550 reverse stock split prior to or upon the effectiveness of the registration statement.
• Obtain approval for listing common stock on the Nasdaq Capital Market; the offering will not proceed without this approval.
• Complete the public offering of common stock and prefunded warrants to raise capital.
• Utilize net proceeds for working capital and general corporate purposes.
• Spend approximately $1 million over the next 12 months on software and hardware development, regulatory approvals, and IP protection for the ZSmile Platform.
• Continue efforts to attract and retain relationships with key dental professionals to educate the consumer market on the ZSmile Platform.
• File necessary reports pursuant to the 1934 Act and report the use of proceeds from the offering.

Key Dates

Recommendation

Dror Ortho-Design is a pre-revenue company with a substantial accumulated deficit and recurring net losses. The independent auditor has expressed 'substantial doubt' about its ability to continue as a going concern, highlighting severe liquidity issues. While the FDA clearance for ZSmile and the large market opportunity are positive, the company's financial instability, high dilution risk from the proposed offering, and the speculative nature of its business model make it a high-risk investment. The stock currently trades on the OTC Pink Market, further limiting liquidity and increasing volatility. A seasoned investor would likely avoid this stock due to the overwhelming financial risks and uncertainties.

Keywords

Orthodontics, Clear Aligners, AI-based Platform, Medical Device, FDA Clearance, ZSmile, Teledentistry, Dental Technology, Reverse Stock Split, Public Offering, Nasdaq Listing, Biomedical, Healthcare Technology, Israel